查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1627883

全球免疫检测市场：预测（2025-2030）

Global Immunoassay Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

免疫检测市场预计将以 6.46% 的复合年增长率成长，从 2025 年的 355.71 亿美元增至 2030 年的 486.44 亿美元。

免疫检测是一种利用抗原抗体亲和性来识别和定量生物检体中目标分子的生物分析方法。在实验室中进行的快速且准确的测试，用于识别特定物质。

癌症、糖尿病、心血管疾病和自体免疫疾病等慢性疾病的增加对免疫检测市场的成长做出了重大贡献，因为它对早期诊断和监测以改善疾病管理具有重要意义。

根据国际糖尿病联盟（IDF）估计，到 2030 年，患有糖尿病的成年人（20 至 79 岁）人数预计将增加到 6.43 亿。 2021年，人​​口约为5.37亿，但预计到2045年将增加至7.83亿。统计数据预测，对早期诊断和明确检测设备的需求将会增加，因此未来对免疫检测的需求也会增加。

此外，感染疾病的流行和发病率的增加正在推动市场的成长。根据世界卫生组织（WHO）2024年5月发布的资料，医疗保健相关感染和抗菌药物抗药性的负担巨大，每年有超过24%的脓毒症患者和52.3%的加护病房患者死亡。药感染疾病患者的死亡率高出两到三倍。

此外，以如何识别各种感染疾病的征兆并采取预防措施为重点的公共卫生教育宣传活动有助于提高公众意识并控制其他疾病。患者意识的提高预计将导致对免疫检测的高需求。

免疫检测市场成长驱动力

  • 慢性病盛行率增加

患有癌症、糖尿病等慢性疾病的患者数量正在增加。这增加了对免疫检测装置检测患者特定生物标记的需求。国际癌症研究机构（IARC）发布了2022年全球各地区新发癌症病例绝对数和癌症发生率统计数据。亚洲癌症病例数最多，占总数的49.2%，有982.6万例。其次是欧洲，占 22.4%，即 4,471,000 人；其次是北美，占 13.4%，即 2,673,000 人。免疫检测对于收集慢性病生物标记以改善患者治疗管理至关重要。此类生物标记透过根据患者的健康状况设计治疗计划、监测治疗反应并在诊断疾病后修改治疗策略来支持个人化医疗保健。

免疫检测市场的地理前景：

  • 预计亚太地区免疫检测市场将显着成长。

由于对稳健的医疗基础设施的投资增加以及慢性病盛行率的增加，预计亚太地区将在免疫检测市场中占据重要地位。日本免疫检测市场呈现稳定成长。其成长的特征是人口老化、慢性病盛行率高以及对早期诊断工具的需求不断增加。日本拥有世界一流的医疗基础设施和高品质的医疗服务，大多数医院、诊所和研究机构都使用免疫检测技术。老年人口占日本总人口的比例逐渐上升，2020年将达到28.56%，2021年将达到28.86%，2022年将达29.00%。 RUO免疫检测是诊断和治疗老年人慢性病的宝贵研究工具。

Sysmex Corporation（总部：日本神户）和 Fujirebio Holdings, Inc.（总部：日本东京）已同意于 2023 年 10 月建立业务合作伙伴关係。该协议将加强我们在免疫检测领域的研发、生产、临床开发、销售和行销等各领域的合作关係。此外，我们也同意签订免疫检测专用试剂和原料的供应协议。透过利用各自的免疫检测专业知识和能力，两家公司将推动全球成长，并为该诊断领域的发展做出重大贡献。

随着超灵敏技术的进步，需求不断增加，特别是在神经感染疾病和肿瘤学检测领域。灵敏度的提高使得能够在所有检测和诊断领域发现较低水平的新标记。因此，新的创新产品的开发预计将在预测期内推动免疫检测市场的发展。

为什么要购买这份报告？

  • 富有洞察力的分析：获得涵盖关键和新兴地区的深入市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、行业和其他子区隔。
  • 竞争格局：了解世界主要企业所采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中发现新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业有用且具有成本效益。

它有什么用？

产业和市场考量、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022年至2030年历史资料与预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争对手的市场状况、策略与市场占有率分析
  • 包括国家在内的细分市场和地区的收益成长和预测评估
  • 公司简介（策略、产品、财务资讯、主要发展等）

免疫检测市场分为以下几个部分进行分析：

按类型

  • 免疫检测（RIA）
  • 酵素免疫分析法测定或酵素结合免疫吸附检测法（ELISA）
  • 计数免疫检测(CIA)
  • 萤光免疫分析(FIA)
  • 化学冷光免疫检测(CLIA)

按治疗区域

  • 感染疾病
  • 骨骼代谢
  • 免疫学
  • 神经生物学
  • 其他的

按最终用户

  • 医院/诊所
  • 诊断实验室
  • 製药和生物技术公司
  • 研究/学术机构

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 法国
  • 德国
  • 义大利
  • 其他的
  • 中东/非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 泰国
  • 台湾
  • 印尼
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章免疫检测市场：依类型

  • 介绍
  • 免疫检测（RIA）
  • 酵素免疫分析法测定或酵素结合免疫吸附检测法（ELISA）
  • 计数免疫检测(CIA)
  • 萤光免疫分析(FIA)
  • 化学冷光免疫检测(CLIA)

第六章免疫检测市场：依治疗领域

  • 介绍
  • 感染疾病
  • 骨骼代谢
  • 免疫学
  • 神经生物学
  • 其他的

第七章免疫检测市场：依最终用户分类

  • 介绍
  • 医院/诊所
  • 诊断实验室
  • 製药和生物技术公司
  • 研究/学术机构

第八章免疫检测市场：按地区

  • 介绍
  • 北美洲
    • 按类型
    • 按治疗区域
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按类型
    • 按治疗区域
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按类型
    • 按治疗区域
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按类型
    • 按治疗区域
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按类型
    • 按治疗区域
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Fujirebio
  • QuidelOrtho Corporation
  • Roche Diagnostics
  • Immunodiagnostic Systems
  • Arbor Assays
  • Beckman Coulter Inc.
  • ImmunoReagents Inc.
  • Abbott
  • Mercodia AB
  • Thermo Fisher Scientific
  • Siemens Healthineers
  • Bio-Rad Laboratories
简介目录
Product Code: KSI061611644

The immunoassay market is estimated to grow at a CAGR of 6.46%, reaching US$48.644 billion by 2030 from US$35.571 billion in 2025.

Immunoassays are bioanalytical methods that employ antigen-antibody affinity to identify and quantify molecules of interest in biological samples. They are quick and accurate tests performed in the lab for the identification of particular substances.

The increase in the cases of chronic illnesses such as cancer, diabetes, cardiovascular, and autoimmune diseases is mostly responsible for the immunoassays market growth as they are important in early diagnosis and monitoring for improved disease management.

The global prevalence of diabetes for the adult (20-79 years) age group is projected to increase to 643 million by 2030, as per the estimates provided by the International Diabetes Federation (IDF). The number is projected to rise to 783 million by 2045, which was around 537 million in 2021. The statistics portray that there will be an increasing need for early diagnosis and apparent detection devices; hence, the requirement for immunoassay will grow in the future.

Additionally, the increasing prevalence and incidence of infectious diseases are fuelling the market growth. As per the World Health Organization data released in May 2024, the burden of healthcare-associated infections and antimicrobial resistance is substantial, with more than 24% of patients with sepsis, 52.3% of patients in the intensive care unit dying every year, and patients with antimicrobial-resistant infections increasing two to three times the death rates.

In addition, public health education campaigns focusing on recognizing the signs of different infectious diseases and how to take precautions against them help in the growing of public awareness and the management of other diseases. This increased patient awareness is expected to lead to high demand for immunoassays.

Immunoassay market growth drivers

  • Increasing Prevalence of Chronic Diseases

There has been an increase in the number of individuals suffering from chronic diseases such as cancer and diabetes, among others. Due to this, there has been a growth in the necessity of immunoassay devices that are used to detect a particular biomarker in a patient. The International Agency for Research on Cancer (IARC) provided statistics on absolute new cases of cancer and cancer incidence in global regions in 2022. In Asia, there was an incidence of 9.826 million cancers, which accounted for the highest number of cases, which was 49.2% of total incidences. Followed by Europe at 22.4% with 4.471 million cancer cases and Northern America at 13.4%, that is, 2.673 million cases of cancers. Immunoassays are essential in the collection of chronic illness biomarkers to improve the treatment management of patients. These assist in medicine personalization, where patients' treatment plans are designed according to their disease condition, followed by monitoring treatment response and modification of the treatment strategy after the disease diagnosis.

Immunoassay market geographical outlook:

  • The Asia Pacific region is expected to witness significant growth in the immunoassay market.

Asia Pacific is poised to hold a prominent position in the immunoassay market, particularly due to its growing investment in robust healthcare infrastructure and the increasing prevalence of chronic diseases. The Japanese immunoassay market is displaying stable growth. Its growth has been characterized by an aging population, a high prevalence of chronic diseases, and increased demand for early diagnostic tools. Japan boasts some of the world's best healthcare infrastructure and quality care, with implementations of immunoassay technologies widespread in most of its hospitals, clinics, and research institutions. The proportion of Japan's elderly population, representing a percentage of the total population, witnessed a gradual increase, reaching 28.56% in 2020, 28.86% in 2021, and 29.00% in 2022. The RUO immunoassay is an invaluable tool for research to diagnose and treat this growing chronic disease ailment in the population.

Further major developments such as Sysmex Corporation, headquartered in Kobe, Japan, and Fujirebio Holdings, Inc., headquartered in Tokyo, Japan, agreed on a business collaboration in October 2023. This agreement enhances their collaboration in various areas, including research and development, production, clinical development, and sales-marketing within the immunoassay field. Additionally, they have agreed on a supply agreement for reagents and raw materials specifically for immunoassay applications. Both companies will leverage their expertise and capabilities in immunoassay, which expedites their global growth and contributes significantly to advancing this field of diagnostics.

With the advancement of ultrasensitive technologies, the demand is increasing, particularly in the neurology infectious disease sector and oncology testing. The higher sensitivity enables, the discovery of new markers at lower levels in all fields, detection, and diagnosis. Hence, in the projected period, with the development of new and innovative product launches, the market for immunoassay is expected to propel.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Immunoassay Market is analyzed into the following segments:

By Type

  • Radioimmunoassay (RIA)
  • Enzyme Immunoassay or Enzyme-linked Immunosorbent Assays (ELISA)
  • Counting Immunoassay (CIA)
  • Fluoroimmunoassay (FIA)
  • Chemiluminescence Immunoassay (CLIA)

By Therapeutic Area

  • Infectious Diseases
  • Bone Metabolism
  • Immunology
  • Neurobiology
  • Others

By End-User

  • Hospitals & Clinics
  • Diagnostics
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Laboratories

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • France
  • Germany
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. IMMUNOASSAY MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Radioimmunoassay (RIA)
  • 5.3. Enzyme Immunoassay or Enzyme-linked Immunosorbent Assays (ELISA)
  • 5.4. Counting Immunoassay (CIA)
  • 5.5. Fluoroimmunoassay (FIA)
  • 5.6. Chemiluminescence Immunoassay (CLIA)

6. IMMUNOASSAY MARKET BY THERAPEUTIC AREA

  • 6.1. Introduction
  • 6.2. Infectious Diseases
  • 6.3. Bone Metabolism
  • 6.4. Immunology
  • 6.5. Neurobiology
  • 6.6. Others

7. IMMUNOASSAY MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Diagnostics
  • 7.4. Pharmaceutical & Biotechnology Companies
  • 7.5. Research & Academic Laboratories

8. IMMUNOASSAY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Therapeutic Area
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Therapeutic Area
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Therapeutic Area
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. UK
      • 8.4.4.2. France
      • 8.4.4.3. Germany
      • 8.4.4.4. Italy
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Therapeutic Area
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Therapeutic Area
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. Japan
      • 8.6.4.2. China
      • 8.6.4.3. India
      • 8.6.4.4. Thailand
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Indonesia
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Fujirebio
  • 10.2. QuidelOrtho Corporation
  • 10.3. Roche Diagnostics
  • 10.4. Immunodiagnostic Systems
  • 10.5. Arbor Assays
  • 10.6. Beckman Coulter Inc.
  • 10.7. ImmunoReagents Inc.
  • 10.8. Abbott
  • 10.9. Mercodia AB
  • 10.10. Thermo Fisher Scientific
  • 10.11. Siemens Healthineers
  • 10.12. Bio-Rad Laboratories